238 related articles for article (PubMed ID: 16411385)
21. [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice].
Schüttrumpf J; Milanov P; Roth S; Seifried E; Tonn T
Hamostaseologie; 2008 Oct; 28 Suppl 1():S92-5. PubMed ID: 18958345
[TBL] [Abstract][Full Text] [Related]
22. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Gui T; Reheman A; Funkhouser WK; Bellinger DA; Hagaman JR; Stafford DW; Monahan PE; Ni H
Thromb Res; 2007; 121(2):225-34. PubMed ID: 17490728
[TBL] [Abstract][Full Text] [Related]
23. [The molecular mechanism of haemophilia B caused by the Arg327Ile novel mutation in FIX gene in vitro expression].
Zhou JW; Dai J; Ding QL; Yu TT; Lu YL; Wang XF; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):642-7. PubMed ID: 23134860
[TBL] [Abstract][Full Text] [Related]
24. The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX.
Blostein M; Cuerquis J; Landry S; Galipeau J
Haemophilia; 2008 Sep; 14(5):1063-8. PubMed ID: 18680528
[TBL] [Abstract][Full Text] [Related]
25. Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B.
Mukherjee S; Saha A; Biswas P; Mandal C; Ray K
Haemophilia; 2008 Sep; 14(5):1076-81. PubMed ID: 18540896
[TBL] [Abstract][Full Text] [Related]
26. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo.
Gui T; Lin HF; Jin DY; Hoffman M; Straight DL; Roberts HR; Stafford DW
Blood; 2002 Jul; 100(1):153-8. PubMed ID: 12070021
[TBL] [Abstract][Full Text] [Related]
27. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
28. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
Enjolras N; Perot E; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Haemophilia; 2015 Jul; 21(4):e317-21. PubMed ID: 25981983
[TBL] [Abstract][Full Text] [Related]
29. Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B.
Goldenberg NA; Bombardier C; Hathaway WE; McFarland K; Jacobson L; Manco-Johnson MJ
Haemophilia; 2008 Jan; 14(1):68-77. PubMed ID: 18005147
[TBL] [Abstract][Full Text] [Related]
30. Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B.
Tatsumi K; Ohashi K; Kataoka M; Tateno C; Shibata M; Naka H; Shima M; Hisanaga M; Kanehiro H; Okano T; Yoshizato K; Nakajima Y; Yoshioka A
Thromb Haemost; 2008 May; 99(5):883-91. PubMed ID: 18449417
[TBL] [Abstract][Full Text] [Related]
31. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
[TBL] [Abstract][Full Text] [Related]
32. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
33. [Double mutation, a 2-bp deletion and Val211Ile, in the blood coagulation factor IX gene of a patient with severe hemophilia B].
Seita I; Shinozawa K; Otaki M; Fujita S; Suzuki T; Amano K; Inaba H; Fukutake K
Rinsho Byori; 2009 May; 57(5):417-24. PubMed ID: 19522246
[TBL] [Abstract][Full Text] [Related]
34. The carboxyl-terminal region of factor IX is essential for its secretion.
Kurachi S; Pantazatos DP; Kurachi K
Biochemistry; 1997 Apr; 36(14):4337-44. PubMed ID: 9100030
[TBL] [Abstract][Full Text] [Related]
35. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition.
Kolkman JA; Mertens K
Biochem J; 2000 Sep; 350 Pt 3(Pt 3):701-7. PubMed ID: 10970782
[TBL] [Abstract][Full Text] [Related]
36. Haemophilia B: impact on patients and economic burden of disease.
Gater A; Thomson TA; Strandberg-Larsen M
Thromb Haemost; 2011 Sep; 106(3):398-404. PubMed ID: 21833450
[TBL] [Abstract][Full Text] [Related]
37. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
[TBL] [Abstract][Full Text] [Related]
38. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
[TBL] [Abstract][Full Text] [Related]
39. Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation.
Sharathkumar A; Hardesty B; Greist A; Salter J; Kerlin B; Heiman M; Sulkin M; Shapiro A
Haemophilia; 2009 Jan; 15(1):91-100. PubMed ID: 18721150
[TBL] [Abstract][Full Text] [Related]
40. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
